cAMP Inhibition Assay

CB Comfort A. Boateng
* *
# #
AN Ashley N. Nilson
# #
RP Rebekah Placide
MP Mimi L. Pham
FJ Franziska M. Jakobs
NB Noelia Boldizsar
SM Scot McIntosh
LS Leia S. Stallings
IK Ivana V. Korankyi
SK Shreya Kelshikar
NS Nisha Shah
DP Diandra Panasis
AM Abigail Muccilli
ML Maria Ladik
BM Brianna Maslonka
CM Connor McBride
MS Moises Ximello Sanchez
EA Ebrar Akca
MA Mohammad Alkhatib
JS Julianna Saez
CN Catherine Nguyen
EK Emily Kurtyan
JD Jacquelyn DePierro
RC Raymond Crowthers
DB Dylan Brunt
AB Alessandro Bonifazi
AN Amy Hauck Newman
RR Rana Rais
BS Barbara S. Slusher
RF R. Benjamin Free
DS David R. Sibley
KS Kent D. Stewart
CW Chun Wu
SH Scott E. Hemby
TK Thomas M. Keck
* *
ask Ask a question
Favorite

D4R- and D2R -mediated inhibition of forskolin-stimulated cAMP production was assayed using the PerkinElmer LANCE UltracAMP assay kit (PerkinElmer, Inc., Waltham, Massachusetts). CHO-K1 cells stably expressing the human D2R long isoform or D4R were maintained in Ham’s F12 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, 800 μg/mL G418, and 300 μg/mL hygromycin at 37 °C, 5% CO2, and 90% humidity. Cells were seeded in 5 μL of Hank’s Balanced Salt Solution (with CaCl and MgCl2) with 5 mM HEPES buffer and 0.2 μM sodium metabisulfite at a density of 5000 cells/well in 384-well white plates. Compounds and forskolin were made in the same buffer. Immediately after plating, cells were treated with 2.5 μL of compound (at various concentrations) and 2.5 μL of forskolin and incubated at room temperature for 30 min. The final concentration of forskolin was 10 μM. When running the assay in antagonist mode, the EC80 of dopamine (10 nM) was added to the forskolin solution. Eu-cAMP tracer and ULight-anti-cAMP solutions were added as directed by the manufacturer, and cells were incubated for 2 h in the dark at room temperature, after which a TR-FRET signal was measured using a BMG Labtech PHERAstar FS (BMG Labtech, North Carolina). Values were normalized to a percentage of the control TR-FRET signal seen with a maximum concentration of dopamine for agonist mode assays and the EC80 of dopamine for antagonist mode assays. Data were collected in triplicate from at least three independent experiments. Data analysis and normalization were performed in GraphPad Prism 9 (GraphPad Software, California). First, raw data was fit using a log(agonist/antagonist) vs response – variable slope (four parameters) curve fit. The data were normalized to the percent maximum dopamine response (agonist mode) or the EC80 of dopamine (antagonist mode). The Hill coefficients of the concentration–response curves did not significantly differ from unity with the data fitting to a single-site model. Graphs are meaned concentration response curves from at least three independent experiments. Data in Table 2 was extracted from the meaned curves where Emax/Imax are expressed as mean ± SEM and the potencies are expressed as mean [95% confidence interval]. Fold selectivities for D4R over the were also calculated and are presented in Table 2.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A